News (USA)

As rival’s version sells well, CEO Martin Shkreli reneges on drug price cut

As rival’s version sells well, CEO Martin Shkreli reneges on drug price cut

TRENTON, N.J. — After weeks of criticism from patients, doctors and even other drugmakers for hiking a life-saving medicine’s price more than fifty-fold, Turing Pharmaceuticals is reneging on its pledge to cut the $750-per-pill price.

Instead, the small biotech company says it’s reducing the price for hospitals by up to 50 percent for its Daraprim, which treats a rare parasitic infection that mainly strikes pregnant women and HIV patients.

The 62-year-old drug had no competition until a furor over the gigantic price hike erupted, triggering multiple government investigations.

Then a pharmacy that compounds prescription drugs for individual patients stepped in and started selling a capsule version for 99 cents.

Imprimis Pharmaceuticals says orders are pouring in from doctors and it says it has dispensed more than 2,500 capsules in barely a month.

© 2015, Associated Press, All Rights Reserved.
This material may not be published, broadcast, rewritten, or redistributed.
Don't forget to share:

Support vital LGBTQ+ journalism

Reader contributions help keep LGBTQ Nation free, so that queer people get the news they need, with stories that mainstream media often leaves out. Can you contribute today?

Cancel anytime · Proudly LGBTQ+ owned and operated

The man who kept gay groups out of Boston’s St. Patrick’s Day Parade has died

Previous article

Pope urges Kenyans to work for peace

Next article